Autologous hematopoietic stem cell transplantation in elderly patients (≥70years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study

Journal of Geriatric Oncology

Volumn 6, Issue 5, 2015, Pages 346-352

  Hermet, E ^a   Cabrespine, A ^a   Guieze R ^a   Garnier, A ^b   Tempescul, A ^c   Lenain, P ^d   Bouabdallah, R ^e   Vilque, J P ^f   Frayfer, J ^g   Bordessoule, D ^h   Sibon, D ⁱ   Janvier, M ^j   Caillot, D ^k   Biron, P ^l   Legros, L ^m   Choufi, B ⁿ   Drenou, B ^o   Gorin, N C ^p   Bilger, K ^q   Tamburini, J ^r   Soussain, C ^s   Brechignac, S ^t   Bay, J O ^a   more..

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHU MORVAN   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g CENTRE HOSPITALIER DE MEAUX   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j Centre René Huguelin   (France)

^k HÔPITAL DU BOCAGE   (France)

^l CENTRE LÉON BÉRARD   (France)

^m CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁿ Hôpital Duchenne   (France)

^o Hôpitaux Universitaires de Strasbourg   (France)

^p HÔPITAL SAINT ANTOINE   (France)

^q HÔPITAL DE HAUTEPIERRE   (France)

^r université Paris Cité   (France)

^s INSTITUT CURIE   (France)

^t AVICENNE HOSPITAL   (France)

more..

Author keywords

Autologous stem cell transplantation; Elderly patients; High dose chemotherapy; Non Hodgkin lymphoma; Treatment related mortality

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; MITOXANTRONE; RITUXIMAB; THIOTEPA;

AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; ELDERLY CARE; ENGRAFTMENT; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; FRANCE; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MORTALITY; NEUTROPHIL COUNT; NON RELAPSE MORTALITY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; T CELL LYMPHOMA; THROMBOCYTE COUNT; VERY ELDERLY; WHOLE BODY RADIATION; BIOLOGICAL THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; LYMPHOMA, NON-HODGKIN; MEDICAL SOCIETY; MULTICENTER STUDY; PREVALENCE; PROCEDURES; SURVIVAL RATE; TRENDS;

AGED; AGED, 80 AND OVER; BONE MARROW TRANSPLANTATION; CELL- AND TISSUE-BASED THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; PREVALENCE; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 84942823889     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2015.04.005     Document Type: Article

References (34)

1. Grulich A.E., Vajdic C.M. The epidemiology of non-Hodgkin lymphoma. Pathology 2005, 37:409-419.
2. Roman E., Smith A.G. Epidemiology of lymphomas. Histopathology 2011, 58:4-14.
3. Hill C., Doyon F. Frequency of cancer at older ages. Bull Cancer 2008, 28:95. (FMC Onco:F7-10).
4. Schmitz N., Buske C., Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol 2007, 44:234-245.
5. Clavio M., Casciaro S., Gatti A.M., Spriano M., Bonanni F., Poggi A., et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996, 81:238-244.
6. Siegel D.S., Desikan K.R., Mehta J., Singhal S., Fassas A., Munshi N., et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999, 93:51-54.
7. Mazza P., Palazzo G., Amurri B., Cervellera M., Manna N., Fellini G., et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report. Bone Marrow Transplant 1999, 23:1273-1278.
8. Sirohi B., Powles R., Treleaven J., Mainwaring P., Kulkarni S., Pandha H., et al. The role of autologous transplantation in patients with multiple myeloma aged 65years and over. Bone Marrow Transplant 2000, 25:533-539.
9. Leger C.S., Bredeson C., Kearns B., Bence-Bruckler I., Atkins H., Huebsch L. Autologous blood and marrow transplantation in patients 60years and older. Biol Blood Marrow Transplant 2000, 6:204-210.
10. Jantunen E., Mahlamäki E., Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60years) with non-Hodgkin's lymphoma: comparison with patients <60years treated within the same protocol. Bone Marrow Transplant 2000, 26:737-741.
11. de la Rubia J., Saavedra S., Sanz G.F., Martín G., Moscardó F., Martínez J., et al. Transplant-related mortality in patients older than 60years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:21-25.
12. Badros A., Barlogie B., Siegel E., Morris C., Desikan R., Zangari M., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70years. Br J Haematol 2001, 114:600-607.
13. Zallio F., Cuttica A., Caracciolo D., Gavarotti P., Bergui L., Giaretta F., et al. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma. Ann Hematol 2002, 81:448-453.
14. Magagnoli M., Castagna L., Balzarotti M., Sarina B., Timofeeva I., Bertuzzi A., et al. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. Am J Hematol 2003, 73:267-272.
15. Bitran J.D., Klein L., Link D., Kosirog-Glowacki J., Stewart C., Raack D., et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003, 9:383-388.
16. Jantunen E., Itälä M., Juvonen E., Leppä S., Keskinen L., Vasala K., et al. Autologous stem cell transplantation in elderly (>60years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006, 37:367-372.
17. Buadi F.K., Micallef I.N., Ansell S.M., Porrata L.F., Dispenzieri A., Elliot M.A., et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006, 37(11):1017-1022.
18. Bishton M., Gilyead M., Das Gupta E., Williams C., Russell N.H., Byrne J.L. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res 2007, 31:1063-1068.
19. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
20. Thomas X., Suciu S., Rio B., Leone G., Broccia G., Fillet G., et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007, 92:389-396.
21. Jantunen E., Canals C., Rambaldi A., Ossenkoppele G., Allione B., Blaise D., et al. EBMT Lymphoma Working Party. Autologous stem cell transplantation in elderly patients (> or =60years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008, 93:1837-1842.
22. Lazarus H.M., Carreras J., Boudreau C., Loberiza F.R., Armitage J.O., Bolwell B.J., et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2008, 14:1323-1333.
23. Andorsky D.J., Cohen M., Naeim A., Pinter-Brown L. Outcomes of auto-SCT for lymphoma in subjects aged 70years and over. Bone Marrow Transplant 2011, 46:1219-1225.
24. Elstrom R.L., Martin P., Hurtado Rua S., Shore T.B., Furman R.R., Ruan J., et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol 2012, 87:433-435.
25. Hosing C., Saliba R.M., Okoroji G.J., Popat U., Couriel D., Ali T., et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65years of age. Ann Oncol 2008, 19:1166-1171.
26. Wildes T.M., Augustin K.M., Sempek D., Zhang Q.J., Vij R., Dipersio J.F., et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:840-846.
27. Jantunen E., Canals C., Attal M., Thomson K., Milpied N., Buzyn A., et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012, 23:166-171.
28. Muta T., Miyamoto T., Fujisaki T., Ohno Y., Kamimura T., Kato K., et al. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Intern Med 2013, 52(1):63-70.
29. Dahi P.B., Tamari R., Devlin S.M., Maloy M., Bhatt V., Scordo M., et al. Favorable outcome in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2014, 20:2004-2009.
30. Chihara D., Izutsu K., Kondo E., Sakai R., Mizuta S., Yokoyama K., et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 2014, 20:684-689.
31. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
32. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat. Med. 1999, 18:695-706.
33. R Development Core Team R: A language and environment for statistical computing 2006, R Foundation for Statistical Computing, Vienna, Austria, (URLhttp://www.R-project.org).
34. Kwiatkowski F., Girard M., Hacene K., Berlie J. Sem: a suitable statistical software adapted for research in oncology. Bull Cancer 2000, 87:715-721.